Clinical Trials Logo

Dermatitis, Contact clinical trials

View clinical trials related to Dermatitis, Contact.

Filter by:

NCT ID: NCT02700373 Completed - Contact Dermatitis Clinical Trials

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Start date: March 2016
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

NCT ID: NCT02614248 Active, not recruiting - Dermatitis, Contact Clinical Trials

The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population

Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the safety and effectiveness of the use of coconut oil for the prevention and treatment of diaper dermatitis among NICU babies at Genesis Medical Center, Davenport.

NCT ID: NCT02534441 Completed - Clinical trials for Allergic Contact Dermatitis

Epidemiology and Co-Reactivity of Novel Surfactant Allergens

Start date: August 2015
Phase: N/A
Study type: Interventional

The primary objectives of this study are to identify positivity rates to three novel surfactants (ingredients used in soaps, detergents, and other cleansers that serve to lower the surface tension of the skin and remove debris) and co-reactivity with other surfactants in patients with known surfactant sensitivity on skin patch testing. The investigators hypothesize that subjects who previously tested positive to known allergenic surfactants (cocamidopropyl betaine, stearamidopropyl dimethylamine, dimethylaminopropylamine, coconut diethanolamide, oleamidopropyl dimethylamine, and decyl glucoside) may demonstrate co-reactivity to the three novel surfactant sensitizers (sodium lauroyl sarcosinate, isostearmidopropyl morpholine lactate, and disodium lauroamphodiacetate) on skin patch testing.

NCT ID: NCT02475512 Terminated - Pressure Ulcer Clinical Trials

Comparison of Wash Wipes and Standard Care in the Prevention of Incontinence-associated Dermatitis in Elderly

Start date: May 2015
Phase: N/A
Study type: Interventional

Incontinence is a widespread problem in all health care setting. One of the main complications of incontinence is inflammation of the skin in the genital and anal region, also known as incontinence-associated dermatitis (IAD). IAD is a known risk factor of pressure ulcer development. Prevalence figures of IAD vary between 5.6% and 50%. The primary aim of this study is to compare the effectiveness of a 3-in-1 genital wipe versus standard care (traditional water and soap) for the prevention of IAD. The second aim is to perform a health economic evaluation of the 3-in-1 genital wipe versus standard care, and third to compare the cost of a 2-in-1 total body wash wipe versus standard care for total body wash. Other outcomes are the comfort and tolerance of both the nurses and participants. In this Randomized Controlled Trial, performed in 13 long-term care settings, the participants will undergo a 30 day study period. In the experimental intervention, the participants will be washed with body wash wipes and genital wipes. In the control group, the subjects will receive traditional care. IAD as well as Pressure Ulcer prevalence will be monitored. Subjective and objective time measurements will be performed.

NCT ID: NCT02028208 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study

Start date: November 4, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the diagnostic performance and safety of ascending doses of mercury, aluminum and palladium metal allergens proposed for inclusion in a metal allergen panel. Optimal dose will be selected based on the lowest dose of each allergen eliciting a positive response in 70-90% of subjects tested.

NCT ID: NCT02028182 Completed - Contact Dermatitis Clinical Trials

Clinical Evaluation of Lyral® Dose Response Study

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine optimal allergen dose as the lowest concentration eliciting positive reactions in 70-90% of subjects. Frequency of positive, negative, doubtful and irritant reactions, and concordance with a corresponding reference allergens will be captured.

NCT ID: NCT02026700 Not yet recruiting - Contact Dermatitis Clinical Trials

Bariederm Cream in Chronic Contact Dermatitis

Start date: February 2014
Phase: N/A
Study type: Interventional

We intend to evaluate the efficiency and tolerability of a barrier cream (bariederm) in protecting hands of individuals with hand dermatitis, either due to allergy or irritation. We believe that the use of the cream would benefit with the skin.

NCT ID: NCT01816542 Not yet recruiting - Allergy Clinical Trials

Evaluation of Irritancy/Allergic Sensitivity to Natural Personal-care Products by Patch Tests

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if any of Mother's Choice' all-natural personal-care products cause either irritation or allergic reaction when applied to both normal or sensitive skin. Each product will be tested on the skin using patch tests.

NCT ID: NCT01798589 Completed - Clinical trials for Allergic Contact Dermatitis

Bioequivalence of Ethylenediamine Dihydrochloride Study

Start date: July 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.

NCT ID: NCT01797562 Completed - Clinical trials for Allergic Contact Dermatitis

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

Start date: December 10, 2012
Phase: N/A
Study type: Interventional

The objective of the study was to evaluate the diagnostic performance and safety of T.R.U.E. Test allergens in pediatric subjects aged 6-17 years old. In total, 11 allergens were evaluated; 7 new allergens on panels 2.2 and 3.2 and 4 previously approved allergens for which changes were made to dose and excipient.